Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Plasma Osteopontin Is a Useful Diagnostic Biomarker for Advanced Non-Small Cell Lung Cancer

  • Han, Seon-Sook (Department of Internal Medicine, Kangwon National University School of Medicine) ;
  • Lee, Seung-Joon (Department of Internal Medicine, Kangwon National University School of Medicine) ;
  • Kim, Woo Jin (Department of Internal Medicine, Kangwon National University School of Medicine) ;
  • Ryu, Dong Ryeol (Department of Internal Medicine, Kangwon National University School of Medicine) ;
  • Won, Jun Yeon (Department of Otolaryngology, Kangwon National University School of Medicine) ;
  • Park, Shinyoung (The Research Department, Kangwon Regional Cancer Center, Kangwon National University Hospital) ;
  • Cheon, Myeong Ju (The Clinical Research Institute of Kangwon National University Hospital)
  • Received : 2013.04.01
  • Accepted : 2013.05.31
  • Published : 2013.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Osteopontin (OPN) and carbonic anhydrase IX (CAIX), which are expressed on the surface of tumor cells, are associated with hypoxia during tumor development and progression. However, the roles of these proteins in the plasma of patients with non-small cell lung cancer (NSCLC) are poorly understood. Herein, we hypothesized that plasma OPN and CAIX levels could be used as diagnostic and prognostic tumor markers in patients with NSCLC. Methods: Fifty-three patients with NSCLC and 50 healthy control subjects were enrolled. We selected controls without malignancy and matched them with NSCLC patient cases according to age and gender. Blood samples were collected at the time of diagnosis; the plasma levels of OPN and CAIX were measured by enzyme-linked immunosorbent assays. Results: The plasma levels of OPN in the patients with NSCLC were significantly elevated as compared to those in the controls (p=0.016). However, there was no difference in the plasma level of CAIX between the NSCLC patients and controls. NSCLC patients with a distant metastasis had a remarkable increase in plasma OPN compared with patients without metastasis (p=0.026), but no such correlation was found for CAIX. There was no difference in overall survival rates according to the plasma level of OPN between the two groups (by Kaplan-Meier survival analysis). Conclusion: Plasma OPN levels were elevated in patients with NSCLC as compared with the controls, with greater elevation of OPN levels in the advanced stages of disease. Therefore, plasma OPN may have utility as a diagnostic, but not prognostic, biomarker of advanced NSCLC.

Keywords

References

  1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300. https://doi.org/10.3322/caac.20073
  2. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998;58:1408-16.
  3. Le QT, Chen E, Salim A, Cao H, Kong CS, Whyte R, et al. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res 2006;12:1507-14. https://doi.org/10.1158/1078-0432.CCR-05-2049
  4. Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer 2004;90:1877-81. https://doi.org/10.1038/sj.bjc.6601839
  5. Weber GF, Lett GS, Haubein NC. Categorical meta-analysis of Osteopontin as a clinical cancer marker. Oncol Rep 2011;25:433-41.
  6. Hu Z, Lin D, Yuan J, Xiao T, Zhang H, Sun W, et al. Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 2005;11:4646-52. https://doi.org/10.1158/1078-0432.CCR-04-2013
  7. Zhao B, Sun T, Meng F, Qu A, Li C, Shen H, et al. Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer. J Cancer Res Clin Oncol 2011;137:1061-70. https://doi.org/10.1007/s00432-010-0968-7
  8. Bramwell VH, Doig GS, Tuck AB, Wilson SM, Tonkin KS, Tomiak A, et al. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res 2006;12(11 Pt 1):3337-43. https://doi.org/10.1158/1078-0432.CCR-05-2354
  9. Mrochem J, Sodowski K, Deja R, Walaszek-Gruszka A, Wojcieszek A, Kolosza Z, et al. Evaluation of selected serum protein markers as early detectors of ovarian cancer. Ginekol Pol 2008;79:271-5.
  10. Abu El Makarem MA, Abdel-Aleem A, Ali A, Saber R, Shatat M, Rahem DA, et al. Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma. Ann Hepatol 2011;10:296-305.
  11. Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN Jr, et al. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol 2008;26:4771-6. https://doi.org/10.1200/JCO.2008.17.0662
  12. Isa S, Kawaguchi T, Teramukai S, Minato K, Ohsaki Y, Shibata K, et al. Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: results from JMTO LC 0004. J Thorac Oncol 2009;4:1104-10. https://doi.org/10.1097/JTO.0b013e3181ae2844
  13. Blasberg JD, Pass HI, Goparaju CM, Flores RM, Lee S, Donington JS. Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer. J Clin Oncol 2010;28:936-41. https://doi.org/10.1200/JCO.2009.25.5711
  14. Winum JY, Scozzafava A, Montero JL, Supuran CT. Inhibition of carbonic anhydrase IX: a new strategy against cancer. Anticancer Agents Med Chem 2009;9:693-702. https://doi.org/10.2174/187152009788680028
  15. Supuran CT, Briganti F, Tilli S, Chegwidden WR, Scozzafava A. Carbonic anhydrase inhibitors: sulfonamides as antitumor agents? Bioorg Med Chem 2001;9:703-14. https://doi.org/10.1016/S0968-0896(00)00288-1
  16. Kim SJ, Rabbani ZN, Vollmer RT, Schreiber EG, Oosterwijk E, Dewhirst MW, et al. Carbonic anhydrase IX in early-stage non-small cell lung cancer. Clin Cancer Res 2004;10:7925-33. https://doi.org/10.1158/1078-0432.CCR-04-0636
  17. Pena C, Lathia C, Shan M, Escudier B, Bukowski RM. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res 2010;16:4853-63. https://doi.org/10.1158/1078-0432.CCR-09-3343
  18. Hyrsl L, Zavada J, Zavadova Z, Kawaciuk I, Vesely S, Skapa P. Soluble form of carbonic anhydrase IX (CAIX) in transitional cell carcinoma of urinary tract. Neoplasma 2009;56:298-302. https://doi.org/10.4149/neo_2009_04_29
  19. Muller V, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer E, et al. Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer. Breast Cancer Res 2011;13:R71. https://doi.org/10.1186/bcr2916
  20. Ilie M, Mazure NM, Hofman V, Ammadi RE, Ortholan C, Bonnetaud C, et al. High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer. Br J Cancer 2010;102:1627-35. https://doi.org/10.1038/sj.bjc.6605690
  21. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-14. https://doi.org/10.1097/JTO.0b013e31812f3c1a
  22. Ahmed M, Behera R, Chakraborty G, Jain S, Kumar V, Sharma P, et al. Osteopontin: a potentially important therapeutic target in cancer. Expert Opin Ther Targets 2011;15:1113-26. https://doi.org/10.1517/14728222.2011.594438
  23. Chakraborty G, Jain S, Behera R, Ahmed M, Sharma P, Kumar V, et al. The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med 2006;6:819-30. https://doi.org/10.2174/156652406779010803
  24. Chang YS, Kim HJ, Chang J, Ahn CM, Kim SK, Kim SK. Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer 2007;57:373-80. https://doi.org/10.1016/j.lungcan.2007.04.005
  25. Wagner PD, Srivastava S. New paradigms in translational science research in cancer biomarkers. Transl Res 2012;159:343-53 https://doi.org/10.1016/j.trsl.2012.01.015
  26. Prasse A, Stahl M, Schulz G, Kayser G, Wang L, Ask K, et al. Essential role of osteopontin in smoking-related interstitial lung diseases. Am J Pathol 2009;174:1683-91. https://doi.org/10.2353/ajpath.2009.080689
  27. Hillas G, Loukides S, Kostikas K, Simoes D, Petta V, Konstantellou E, et al. Increased levels of osteopontin in sputum supernatant of smoking asthmatics. Cytokine 2013;61:251-5. https://doi.org/10.1016/j.cyto.2012.10.002

Cited by

  1. Osteopontin as a therapeutic target for cancer vol.18, pp.8, 2013, https://doi.org/10.1517/14728222.2014.925447
  2. The prognostic value of osteopontin expression in non-small cell lung cancer: a meta-analysis vol.45, pp.5, 2013, https://doi.org/10.1007/s10735-014-9574-3
  3. Correlation between lung neoplasm and serum level of osteopontin: A meta-analysis vol.4, pp.5, 2016, https://doi.org/10.3892/br.2016.619
  4. Clinical Significance of Circulating Osteopontin Levels in Patients With Lung Cancer and Correlation With VEGF and MMP-9 vol.34, pp.8, 2013, https://doi.org/10.1080/07357907.2016.1223301
  5. OPN promotes the aggressiveness of non-small-cell lung cancer cells through the activation of the RON tyrosine kinase vol.9, pp.1, 2013, https://doi.org/10.1038/s41598-019-54843-2